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Arsenic contamination of drinking water is a real public health problem in certain areas 
of South-East Asia where chronic exposure has been correlated to higher rates of lung, skin, 
bladder, kidney, and liver cancer. Although arsenic carcinogenicity is well established, the 
mechanism by which it induces cancer is poorly understood. Recent evidence suggests that 
oxidative stress could be a possible mechanism for the carcinogenic effects of arsenic. Selenium, 
in the form of selenocysteine, is necessary for the activity of several enzymes with a role in the 
defense against reactive oxygen species (ROS), primarily thioredoxin reductases (TrxR) and 
glutathione peroxidases (Gpx). One of the key enzymes in the incorporation of Se into 
selenoproteins is selenophosphate synthetase (SPS). SPS catalyzes the activation of Se to 
selenophosphate, and is the first step in the pathway of selenoprotein biosynthesis. SPS contains 
a conserved vicinal dithiol motif (CXC) within a region of amino acids that have been predicted 
to be a selenium binding site. Our hypothesis is that arsenite inhibits new selenoprotein 
synthesis, thus indirectly increasing the level of ROS.  
In this study we have developed a spectrophotometric assay for SPS. Using this assay, we 
have determined that arsenite inhibits SPS activity. Kinetic analysis of this inhibition showed 
that arsenite, a trivalent form of arsenic, acts as a competitive inhibitor with the substrate, sodium 
selenide. This inhibition of SPS could represent a potential molecular mechanism for oxidative 
stress induced upon arsenite treatment of human cell lines in culture. To further study the effects 
of trivalent arsenicals at a cellular level we decided to use a human keratinocyte cell line, HaCaT 
as a cell culture model. Our study showed that although arsenite does not alter cell proliferation 
iii 
or protein synthesis, it specifically inhibits new selenoprotein synthesis. However, short term or 
long term exposure of HaCaT cells to arsenite failed to result in changes to Gpx and TrxR levels. 
Since the radioisotope selenium used in labeling studies is selenite, these results indicate 
that an alternate source of selenium may bypass the inhibitory effects of arsenite. Future studies 
will focus on studying the effects of arsenicals on keratinocytes cultured in a defined medium 
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CHAPTER ONE: INTRODUCTION AND LITERATURE REVIEW 
1.1- Importance of selenium  
 The metalloid selenium exists naturally in organic (e.g. selenomethionine, 
selenocysteine) and in inorganic forms (e.g. selenite, selenate, selenide) (Birringer M., 
2002). Selenium compounds need to be metabolized into an inorganic precursor, selenide 
(NaHSe), before being inserted into proteins as the 21st amino acid selenocysteine that is 
essential for the catalytic function of selenoenzymes (Carlson B.A., 2004). Selenium is 
required in several mammalian enzymes with roles in defense against reactive oxygen 
species. These include thioredoxin reductase (TrxR), several isoforms of glutathione 
peroxidase (Gpx) and a selenium-dependent form of methionine sulfoxide reductase 
(SelR) (Tamura T., 1996, Arner, E. S., 2000, Lee S. R. et al., 2000, Flohe, L. et al., 1973, 
Brigelius-Flohe, R., 1999, Chambers, I. et al., 1986, Kryukov, G. V. et al., 2002). In a 
recent article, using a computational approach, the authors (Kryukov, G.V. et al., 2003) 
have shown that 25 genes encoding selenoproteins reside in the sequenced human 
genome (Table 1). All selenoproteins with known enzymatic functions contain 
selenocysteine in their catalytic center. Selenoproteins incorporate SeCys 
cotranslationnally into the polypeptide chain by a complex mechanism (Low, S.C., 1996) 





Table 1: Mammalian Selenoproteins 
Selenoprotein  Common abbreviations Key references 
Glutathione peroxidase  GPx 
Cytosolic or classical GPx  cGPx, GPx-1  Mills G.C.  1957  
Phospholipid hydroperoxide GPx  PHGPx, GPx-4  Ursini F. 1982  
Plasma GPx  pGPx, GPx-3  Takahashi K. 1987  
Gastrointestinal GPx  GI-GPx, GPx-GI, GPx-2  Chu F-F. 1993  
Iodothyronine deiodinases    
50-deiodinase, type I  50DI  Behne 1990, Arthur 1990  
50-deiodinase, type II  50DII  Davey J.C. 1995  
5-deiodinase, type III  5-DIII  Croteau W. 1995  
Thioredoxin reductases  
Thioredoxin reductase TR Tamura T. 1996
Mitochondrial thioredoxin reductase  TR-2  Lee 1999, Watabe 1999, Miranda-Vizuete 1999 
Thioredoxin reductase homologs  SelZf1, SelZf2  Lescure A. 1999 
Selenophosphate synthetase-2   Guimaraes M.J. 1996 
15-kDa selenoprotein (T cells)   Gladyshev V.N. 1998 
Selenoprotein P  SelP  Motsenbocker, M.A. 1984 
Selenoprotein W  SelW  Vendeland S.C. 1995 
Selenoprotein R  SelR  Kryukov G.V. 1999 
Selenoprotein T  SelT  Kryukov G.V. 1999 
Selenoprotein X  SelX  Lescure A. 1999 




1.2- Selenoprotein biosynthesis 
The process by which selenocysteine is inserted via translation of a UGA codon 
(normally a stop codon) is well described in Escherichia coli (Bock, A., 1991, Leinfelder, 
W. et al., 1990), and is currently being characterized in mammals (Berry, M. J. et al., 
1997, Berry, M. J. et al., 2002).  A specific tRNA is first loaded with serine, and then 
transformed into selenocysteyl-tRNA using selenophosphate as the activated Se donor. 
The common UGA stop codon is recoded by SelB, a translation factor in the presence of 
a SeCys-charged tRNA and a 3’ untranslated region (SECIS) (Figure 1) (Forchhammer, 
K., et al., 1990, Forster C. et al., 1990).  
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Figure 1: Nucleotide sequence of tRNASec from a eukaryotic source. Bovine liver 
tRNASec (Hatfield D., 1985) containing an esterified serine is converted to selenocysteyl-
tRNASec  (Lee B.J. et al., 1989). 
 
Similar to the bacterial system, the coordination of the synthesis of specific 
selenocysteine-charged tRNA, elongation factors, and a consensus sequence allows tight 
post-transcriptional regulation of selenoprotein biosynthesis by Se in mammals (Flohe L. 
et al., 1997). The consensus sequence in a stem-loop RNA structure is located in the 3’ 
untranslated region (UTR) of the mRNA and known as a SECIS element for SeCys 
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insertion sequence (Kryukov, G. V., 1999). This regulation and specificity is needed in 
all biological systems that express selenoproteins in order to prevent read-through of 
normal stop codons and non-specific incorporation of selenium into sulfur-containing 
amino acids and enzyme cofactors.  
 
 
1.3- Selenium deficiency 
In mammals, when the Se supply is limited, the selenoproteins are individually 
synthesized based on their most essential functions (Behne, D., Kyriakopoulos, A., 1993). 
Several studies demonstrated that the mRNA levels of the selenoproteins fluctuate 
differently depending on the tissue concerned. In fact, Bermano et al. showed that with 
H4 hepatoma cells (Bermano G. et al., 1996), as with H3B and HL-60 myeloid cells 
(Baker, R.D. et al., 1993, Chada, S. et al., 1989), culture in medium without a supplement 
of sodium selenite led to the cells becoming Se-depleted. After 3 days in such medium 
the H4 cells had lost 80% of their cGpx activity. This loss of cGpx activity was 
accompanied by a reduction in cGpx mRNA and a smaller reduction in PHGpx activity, 
although there was no change in PHGpx mRNA abundance (Bermano G. et al., 1996).  
 





Selenium deficiency causes a decrease in the concentrations of most 
selenoproteins but selenoprotein P and type I iodothyronine 5'-deiodinase (5'-deiodinase) 
are more resistant to this effect than is glutathione peroxidase. It has been shown that 
levels of all 3 mRNAs encoding deiodinase, selenoprotein P and Gpx decreases 
progressively with time by feeding a selenium-deficient diet to weanling rats for 14.5 
weeks. In these experiments, mRNA decreases was correlated to decreases in Gpx 
activity and selenoprotein P concentration. These results suggest that synthesis of Gpx 
and selenoprotein P is limited to a similar extent at the translational level by the 
availability of selenium (Hill, K E. et al. 1992).  
 
 
1.4- Selenoproteins with known function 
1.4.1- Thioredoxin reductase (TrxR) 
TrxR catalyzes the NAPDH-dependent reduction of oxidized thioredoxin. 
Reduced thioredoxin provides reducing equivalents for processes such as reduction of 
ribonucleotides to deoxyribonucleotides by ribonucleotide reductase (Holmgren, A., 
1989) and is also considered a regulator of cellular redox balance (Follmann, H., 
Haberlein, I., 1996), (Powis, G. et al., 1994). TrxR has been the focus of investigations 
for several decades but was first identified as a selenoprotein by Tamura and Stadtman in 
1996 (Tamura, T, Stadtman, T.C., 1996). TrxR is a FAD-containing disulfide reductase 
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that plays an important role in cell proliferation (Holmgren, A., 1985). The important role 
of the pool of reduced thioredoxin in DNA synthesis and gene transcription implicates 
TrxR as a key enzyme in the control of cell growth. Mammalian forms of TrxR are not 
well characterized but rat liver TrxR has been previously isolated as a 116 kDa 
homodimer. (Luthman, M., Holmgren, A., 1982). The larger mammalian enzyme is a 
selenoprotein containing a SeCys residue in the sequence Cys-SeCys-Gly at the C-
terminus of each subunit. (Tamura, T., Stadtman, T.C., 1996, Gladyshev, V.N. et al., 
1996, Liu S.Y. Stadtman, T.C., 1997, Gasdaska, P.Y. et al., 1995). 
 
 
1.4.2- Glutathione peroxidase (Gpx) 
Gpx was the first mammalian selenoprotein identified (Flohe, L. et al., 1973), and 
as such is the best characterized mammalian selenoenzyme. In fact, the family of 
selenium-dependent Gpx comprises several isoforms of Gpx with differing specificity 
and expression patterns in different tissues that have been uncovered in recent years. The 
four distinct isoforms are: 1) a classic tetrameric cytosolic cGpx which is the most 
ubiquitous; 2) gastrointestinal cytosolic isozyme GIGpx; 3) a secreted form plasma 
isozyme pGpx which is released from the kidney into the plasma; and 4) the monomeric 
membrane associated phospholipid hydroperoxide PHGpx preferentially expressed in 
testis (Brigelius-Flohe, R., 1999).  Each of these enzymes catalyzes the thiol-dependent 
reduction of hydroperoxides to their corresponding alcohols.  The former three are 
involved in the neutralization of hydrogen peroxide (H2O2) via the regeneration of 
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glutathione (GSH), their main substrate, with the latter acting on phospholipid 
hydroperoxides. Mammalian glutathione peroxidases in the reduced form contain an 
ionized selenol that can react with an organic peroxide or H2O2, to form an enzyme-
selenenic acid (RSeOH) intermediate. PHGpx neutralizes oxidized membrane lipids, has 
a broader specificity for cholesterol and phospholipid hydroperoxides, and has been 
recently shown to regulate the activity of lipoxygenases (Straif, D. et al., 2000, Werz, O., 
Steinhilber, D., 1996, Ursini, F. et al., 1999, Flohe, L., 1989, Ursini, F. et al., 1995). 
 
 
1.4.3- Methionine sulfoxide reductase (Msr) 
A new selenoprotein identified both by radioisotope labeling and bioinformatic 
techniques (Kryukov, G.V. et al., 1999) has been shown to be a form of methionine 
sulfoxide reductase (Kryukov, G.V. et al., 2002) and has been termed SelR.  Msr proteins 
convert free methionine sulfoxide and methionine sulfoxide residues in oxidatively 
modified proteins back to methionine in a thioredoxin-dependent manner (Brot, N. et al., 
1982, Lowther, W.T. et al., 2002, Moskovitz, J. et al., 2002).  Recent knockout and 
expression studies looking solely at the non-selenium dependent forms of these enzymes 
underline the important role these enzymes play in aging and oxidative stress. Studies 
have shown that the cyclic interconversion of Met and MetO residues of proteins is 
involved in several different biological processes such as: 1) an antioxidant mechanism 
for the scavenging of ROS; 2) the regulation of enzyme activities; and 3) cell signaling 
(Stadtman, E.R. et al., 2003). In the same study, they also postulated that a decrease in 
 9




1.4.4- Selenophosphate synthetase (SPS)  
E. coli SPS is a 37 kDa enzyme that catalyzes the formation of selenophosphate 
(SeP03-), a reactive selenium (Se) donor compound from ATP and selenide and releases 
the beta-phosphate as orthophosphate (Leinfelder, W. et al., 1990). SPS has been isolated 
from an overproducing E. coli strain and purified (Veres, Z. et al., 1994, Lacourciere 
G.M., Stadtman, T., 1999). SPS uses a reduced form of selenium (NaHSe in the in vitro 
assay) and ATP to generate selenophosphate. From the gene sequence, E. coli SelD 
contains 7 cysteine residues, 2 of which are located at positions 17 and 19 in the sequence 
-Gly-Ala-Cys-Gly-Cys-Lys-Ile- (Leinfelder, W. et al., 1990). Mutation in SelD gene 
eliminates the ability of E. coli to incorporate selenium into selenoprotein. Inactivation of 
the SPS enzyme by alkylation with iodoacetamide indicated that at least one cysteine 
residue in the protein is essential for enzyme activity. Based on DNA sequence, a 
selenocysteine residue occurs in some eukaryotes and prokaryotes and in at least one of 













Organism             Conserved N-terminal domain sequence        
Escherichia coli   LTQYSHGAGCGCKISPKVL 
Salmonella typhimurium  LTQYSHGAGCGCKISPKVL 
Yersinia pestis CO92  LTQYSHGAGCGCKISPKVL 
Haemophilus influenzae       LTQYSHGAGUGCKISPKVL 
Homo Sapiens SPS2   LTGFSGMKGUGCKVPQEAL 
Homo Sapiens SPS1   LTRFTELKGTGCKVPQDVL 
Mus musculus SPS2   LTSFSGMKGUGCKVPQETL 
Mus musculus SPS1   LTRFTELKGTGCKVPQDVL 
 
U = selenocysteine 
Sequences were derived from DNA sequences in the Genbank database 
(NCBI,NIH) 
       
Figure 3: Conserved Proximal dithiol/selenol motif in primary sequence of selected 
bacterial and mammalian SPS 
 
  This SeCys residue is located proximal to a cysteine in a conserved motif (UXC) 
within the N-terminal region of SPS and corresponds to a required cysteine residue in the 
E. coli enzyme, based on site-directed mutagenesis (Kim, I.Y. et al., 1992).  
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In these mutagenesis studies, these cysteine residues were mutated to serine 
residues. The authors tested the biological activities of the wild type and mutant proteins 
using E. coli MBO8 (selD-) transformed with plasmids containing the wild type and 
mutant selD genes. Their results showed that the plasmid containing the Cys17-mutated 
gene failed to complement the selD- mutation in MBO8, whereas the Cys19-mutated gene 
was indistinguishable from wild type. The mutant proteins, like the wild type enzyme, 
bound to an ATP-agarose matrix, demonstrating that their affinities for ATP were 
unimpaired. Selenide-dependent formation of AMP from ATP was abolished by mutation 
of Cys17, but the Cys19 mutation had no effect on the ability of the enzyme to catalyze the 
reaction. These mutagenesis studies indicated that Cys17 has an essential role in the 
catalytic process that leads to the formation of selenophosphate from ATP and selenide.  
Analysis of the total genomic sequences of Methanococcus jannaschii and 
Haemophilus influenzae (Bult, C.J. et al., 1996), (Fleishmann, R.D. et al., 1995) revealed 
that the selD gene in these organisms possesses a TGA codon at the position of the E. coli 
Cys-17, indicating the presence of a SeCys residue. Moreover, SeCys-containing variants 
also were identified in mouse and human enzymes (Guimaraes, M.J. et al., 1996), 
(Wilting, R. et al., 1997). Replacement of the SeCys residue of the mouse enzyme with 
cysteine decreased but did not abolish enzyme activity (Kim, I.Y. et al., 1997), whereas 
changing Cys-17 of SelD to Ser destroyed catalytic activity (Kim, I.Y., 1992). The 
second group of SelD homologs present in human, mouse, and Drosophila share high 
sequence similarity with the bacterial SPS but lack a cysteine or SeCys residue in the 
position that corresponds to Cys-17 of the E. coli enzyme. The human homolog has a 
threonine substitution, and a homolog from Drosophila melanogaster contains an 
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arginine (Low, S.C. et al., 1995) (Persson, B.C. et al., 1997).  However the role of 
selenocysteine in the human SPS2 enzyme catalysis is still not known. 
Marla Berry and collaborators (Low, S.C. et al., 1995, Low, S.C. et al., 1995) 
cloned and sequenced mouse and human genes exhibiting regions of homology with the 
E. coli selenophosphate synthetase (selD) gene. The human gene sequence encoded a 
motif GTGCK (residues 28-32) resembling the E. coli 16-20 residue segment except that 
Cys-17 was replaced with threonine. Expression of the human gene was shown to 
regulate the synthesis of 75Se-labeled 5' deiodinase, providing evidence of the production 
of selenophosphate by human SPS1. Especially interesting is the finding that an 
analogous gene detected in the mouse embryo at early stages of development contains an 
N-terminal sequence region corresponding to the E. coli residue 16-20 segment except 
that a selenocysteine residue is encoded in place of the essential Cys-17 residue as shown 
in figure 3 (Zlotnik, A. et al., 1995, Guimaraes, M.J. et al., 1995). 
SPS represents the first defined step in the specific incorporation of 
selenocysteine into selenoproteins, since the transport and reduction of selenium has not 
been defined at the molecular level. Although trafficking of selenium to SPS is poorly 
understood, recent evidence indicates that a selenium binding protein (Self, W.T. et al, 
2004) may be involved in linking transport and reduction of Se to SPS in a bacterial 
model system. Previous kinetic studies under strictly anaerobic conditions reported an 
apparent Km of 7.3µM for sodium hydrogen selenide (NaHSe) using E.coli SPS (Veres, 
Z., 1994). The authors measured the formation of AMP from ATP after separation 14C-
labeled nucleotides by thin layer chromatography (TLC). Although NaHSe is the only 
known substrate for SPS, it is likely that physiological concentrations of NaHSe do not 
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exceed nanomolar levels. Thus, the trafficking of Se to SPS is still a key issue to be 
resolved in Se metabolism. 
 
 
1.5- Arsenic as a carcinogenic metalloid 
 Industries release quantities of numerous metals and metalloids such as arsenic 
(As) into the environment exposing humans to elevated concentrations of these toxic 
elements. Inorganic As is also naturally occurring, ubiquitous in the environment in the 
form of trivalent (AsIII) as well as pentavalent (AsV) species (Hei, T.K., Filipic, M., 
2004). Unlike selenium, arsenic has no known role in biology. In contrast to selenium, 
arsenic has been implicated as a contributing factor in carcinogenesis (Hughes, M. F., 
2002). Biologically, the trivalent sodium arsenite is more toxic than the pentavalent 
sodium arsenate (Barrett, J.C. et al., 1989). Chronic exposure to arsenic is associated with 
skin, lung, liver and bladder cancers with skin being the major target, (Germolec, D.R. et 
al., 1998, Landsdown, A.B., 1995, Phillip, R., 1985), however the biochemical 
mechanism of this arsenic-induced carcinogenesis is not well described. 
 Cultured mammalian cells have provided some possible mechanisms by which 
arsenical compounds may exert a carcinogenic activity. Sodium arsenite and sodium 
arsenate were observed to induce morphological transformation such as enhanced colony-
forming efficiency of Syrian hamster embryo cells in a dose-dependent manner (Lee, 
T.C. et al., 1985. The trivalent sodium arsenite was more potent sulfhydryl depleting 
agent by oxidation of GSH to GSSG than the pentavalent sodium arsenate (Winski, S.L., 
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Carter, D.E., 1995). A recent study has demonstrated that arsenite treatment of cultured 
cells results in the production of reactive oxygen species and a prolonged oxidative stress 
correlated with a consistently high level of Heme oxygenase I mRNA (Gabis, K.K. et al., 
1996, Takahashi, S. et al., 1998). DNA microarray studies demonstrated early 
upregulation of three different TrxR genes following arsenite treatment (Hamadeh, H.K. 
et al., 2002, Rea, M.A. et al., 2003). It is clear from these studies that treatment of 
cultured mammalian cells results in oxidative stress, yet the molecular mechanism behind 
this oxidative stress is unknown.  
 
 
1.6- Arsenite interactions with glutathione 
 Arsenite, the predominant trivalent species of arsenic in the environment, is 
known to react with intracellular thiols such as glutathione (GSH) (Scott, N. et al., 1993). 
Reactions between GSH and arsenite have been characterized using 1H and 13C NMR. 
These investigators followed binding of As to GSH through the thiol group by shifts in 
the carbon atom bonded to the sulfhydryl group of the cysteinyl residue, i.e., the CH2 
carbon atom and the protons bonded to it. Sodium arsenite, As(III), bound to GSH to 
form an As(SG)3 complex in solution as indicated by NMR spectra. The toxicity of 
arsenite has been attributed to the inhibition of enzymes with proximal or vicinal thiol 
residues, such as the lipoamide-dependent α keto-acid dehydrogenases of the Krebs cycle 
(Lin, S. et al., 2001, Gorin, Y., Leseney, A.M., 1997, Cavigelli, M. et al., 1996). More 
recently, TrxR has also been shown to be inhibited by trivalent arsenic compounds both 
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in vitro and in vivo (Lin, S. et al., 1999, Styblo, M., Thomas, D. J., 1995). However, 50% 
inhibition required greater than 100 µM arsenite. Other members of the pyridine-
nucleotide dependent family of oxidoreductases, such as GSH reductase, have also been 
shown to be inhibited by arsenite and other trivalent arsenic species (Styblo, M., Thomas, 
D. J., 1995). Each of the pyridine-nucleotide dependent oxidoreductases has conserved 
proximal cysteines (and/or selenocysteines) within their active sites.  It is presumed that 
arsenite is reacting with and/or binding to these sites in the inhibition of these enzymes, 
although direct binding studies have not been performed. Arsenite has high affinity to 
GSH and free radicals induced by arsenite can oxidize GSH, hence depleting the level of 
antioxidant. Arsenic-thiol interactions were investigated by determining changes in rat 
blood sulfhydryls after exposure to arsenate, As(V), or arsenite, As(III). (Winski, S.L., 
Carter, D.E., 1995). 
 
 
1.7- As/Se mutual sparing effect 
The first experimental evidence indicating a link between the metabolism of 
inorganic arsenic and selenium was reported more than 60 years ago (Moxon, A. L., 
1938) after feeding rats with sodium arsenite (in drinking water) along with seleniferous 
grains in order to prevent Se poisoning. In these studies, the poisonous arsenite was 
capable of preventing toxic effect of selenium, thus, these metalloid displayed a mutual 
sparing effect. Later studies demonstrated that the chronic ingestion of arsenite abolishes 
the anticarcinogenic effect of Se in rats ( Ip, C.; Ganther, H. E. 1988), providing a 
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potential explanation of the association of cancer with prolonged As intake in humans 
(Chen, C.J. et al.; 1988, Wu, M.M. et al., 1989). In fact, several studies showed the link 
between high As/Se ratio (lung, blood) and carcinogenesis. (Wester, P.O. et al., 1981; 
Wang , C.T. 1996). Research on Blackfoot disease patients proved As to be the major 
causative agent of the disease and the authors attributed the decrease of Se to the 
antagonistic effect of arsenic (Wang, C.T. et al., 1993). Blackfoot disease (BFD) is a 
severe form of peripheral vascular disease, in which the blood vessels in the lower limbs 
are severely damaged, resulting eventually in progressive gangrene. This disease has 
been limited to certain areas of Taiwan with elevated levels of arsenic. 
More recent studies on residents living in an As-contaminated area in Bangladesh 
corroborated the previous observation by suggesting that As alters Se metabolism, 
increasing Se excretion through bile or feces (Miyazaki, K. et al., 2003). 
 
 
1.8- Arsenic and Selenium containing thiol conjugates 
Previous studies have shown seleno-bis (S-glutathionyl) arsinium ion 
[(GS)2AsSe]-  to be the major As and Se excretory product in bile of rabbits treated with 
arsenite and selenite (Gailer, J. et al., 2002, Gailer, J., 2002). In these studies, the authors 
have intravenously injected rabbits with different combinations of the arsenic and 
selenium oxo-anions (arsenite + selenate, arsenate + selenite, and arsenate + selenate) and 
analyzed the collected bile and whole blood samples by X-ray absorption spectroscopy. 
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Only the injection of arsenite and selenate led to the biliary excretion of [(GS)2AsSe]- 
within 25 min. In these studies, the stability of the compound was not addressed. 
 The antagonism between arsenite and selenite may have its molecular basis in the 
formation the arsenic-selenium compound. Previous work on the metabolism of 
arsenate(AsV) and selenate in mammals (mice and rabbits) by determination of arsenic 
metabolites in plasma and urine after administration of [74As] arsenate revealed that these 
compounds are individually reduced in vivo to arsenite (AsIII) (Vahter, M., Envall, J., 
1983, Vahter, M., Marafante, E. 1985) and selenite (Kobayashi, Y. et al., 2001). When As 
and Se are co-administered, a mutual inhibition of the individual methylation pathways 
occurs and this may be explained by the formation of [(GS)2AsSe]- (Levander, O. A.; 
Argrett, L. C., 1969; Hsieh, H. S.; Ganther, H. E., 1975; Zakharyan, R. et al.; 1995). 
The biliary excretion of [(GS)2AsSe]- may be especially important in view of the fact that 
prolonged exposure to inorganic arsenic in drinking water significantly reduces tissue 
selenium concentrations ( Wang, C.T., 1996). Discovery of the As-Se complex  may be 
used against the pathological effects of inorganic arsenic in drinking water (in 
Bangladesh for example) by increasing the daily intake of selenium leading to the 
formation and excretion of [(GS)2AsSe]-. 
Based on known interactions of As with vicinal dithiols and the fact that 
selenophosphate synthetase also contains a proximal cysteine motif (Figure 3), we have 
tested the possibility that arsenite and/or (GS)2AsOH (AsIII) would inhibit SPS. In order 
to facilitate this kinetic analysis, we have developed a spectrophotometric assay to 
analyze the initial rate of selenide-dependent production of inorganic phosphate     
(Figure 5) from E. coli SPS. We also determined whether As treatment of cultured cells 
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(Hela and HaCaT keratinocyte) would have an effect on the incorporation of Se into 
selenoproteins using the radioisotope 75Se. A better understanding of the interrelationship 
of arsenic and selenium could lead to a possible mechanism of arsenic-induced 
carcinogenicity that may open a door towards an efficient treatment of population 






CHAPTER TWO: MATERIALS AND METHODS 
2.1- Selenophosphate synthetase spectrophotometric assay 
2.1.1- Assay Principle 
A coupled assay for the determination of inorganic phosphate (Pi) described by 
Webb (Webb, M.R., 1992) was used to follow NaHSe-dependent SPS activity. This 
sensitive enzymatic assay was used to monitor the kinetics of phosphate release by SPS 
in solution through formation of a chromophoric product. In the presence of inorganic 
phosphate (Pi), 2-amino-6-mercapto-7-methylpurine riboside (MESG) is converted by 
purine nucleoside phosphorylase (PNP) to ribose 1-phosphate and 2-amino-6-mercapto-
7-methylpurine.  
An increase in absorbance at 365 nm is monitored spectrophotometrically and 






Figure 4: Enzymatic conversion of 2-amino-6-mercapto-7-methylpurine riboside 
(MESG) to ribose 1-phosphate and 2-amino-6-mercapto-7-methylpurine by purine 
nucleoside phosphorylase (PNP). The accompanying change in absorption at 365 nm 
allows quantitation of inorganic phosphate (Pi) consumed in the reaction. 
 
 
2.1.2- Synthesis of sodium hydrogen selenide 
NaHSe was synthesized as previously described (Klayman, D.L., Griffin, T.S., 
1972). The reagents were purchased from Acros Organics. All the reactions were 
performed in an anaerobic chamber (Coy Laboratory Products, Inc. Grass Lake, 
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Michigan). Equation (1) summarizes the reaction of sodium borohydride with elemental 
Se to yield sodium hydrogen selenide. 
 
4NaBH4 + 2Se + 7H2O           2NaHSe +Na2B4O7+ 14H2   (1) 
 
Aqueous solution of sodium borohydride (1.5 mM) was added drop wise at room 
temperature to an aqueous solution of metallic selenium (0.725 mM) in a 2:1 molar ratio. 
The reaction was completed within 15 minutes and colorless NaHSe resulted (590 mM 
final concentration). NaHSe was separated from residual borate by passage through a 
G10 column (30 X 1 cm from Sigma-Aldrich) and stored at room temperature under 
anaerobic conditions until used as a selenium substrate for SPS assays. 
 
 
2.1.3- Spectrophotometric assay procedure 
The assay was performed at 37 °C in an anaerobic cuvette (Fisher Scientific) due 
to oxygen sensitivity of the NaHSe and the product selenophosphate according to 
equation (Figure 5) (Bock, A., Stadtman, T.C., 1988; Kramer, G.F., Ames, B.N. 1988; 
Wittwer, A.J., Stadtman, T.C. 1986).  
 
NaHSe +ATP → SePO4 + AMP + Pi 
     Figure 5: Overall Reaction catalyzed by SPS  
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The reaction buffer included 100 mM Tris (ICN Biomedicals), 20 mM KCl 
(Fisher Scientific), 4 mM MgCl2 (Alfa Aesar) and the pH was adjusted to 7.2. All the 
reagents were degassed in the anaerobic chamber prior to use. The 700 µl reaction 
mixture contained: 0.2 mM MESG substrate, 1 U of purine nucleoside phosphorylase 
(PNP) (Molecular Probes), 2 mM ATP (Alexis Biochemicals), variable concentrations of 
E. coli SPS and NaHSe. The reaction mixture was equilibrated to 37 °C in a sealed 
anaerobic cuvette (Fisher Scientific) using a thermostattable cell holder incorporated in 
the Agilent 8453 UV-Visible spectroscopy system (Alpha-Omega Technologies, Inc., 
Brielle, New Jersey). A uniform temperature was maintained by circulating water from a 
thermostatted water bath through the manifold. The spectrophotometer was first blanked 
using previously cited mixture without ATP and NaHSe. A baseline activity reading was 
taken prior to the addition of ATP using a gas-tight syringe. The NaHSe-dependent 
production of Pi was measured by ascertaining the increase in absorbance at 365 nm as 
previously described (Figure 6). For SPS inhibition studies, sodium arsenite was diluted 
for each experiment from a 100 mM stock solution and different concentrations (10, 17.5 
and 25 µM) added anaerobically before the substrate selenide which was incorporated 


































Figure 6: Representative SPS Assay: NaHSe-dependent production of Pi. The arrows 
indicate the times of addition of the reagents.   
 
 
2.1.4- Synthesis of Seleno-bis (S-glutathionyl) arsinium ion [(GS)2AsSe]-  
All the reactions and purification were performed under anaerobic conditions at room 
temperature. NaHSe was previously made for SPS assay. 
• As(OH)3 + 2GSH           (GS)2AsOH + 2H2O 
• (GS)2AsOH + NaHSe           [(GS)2AsSe]- + 2H2O 
 
(GS)2AsOH  (0.1 mM) was prepared by mixing aqueous GSH (0.2 M) and sodium 
arsenite solution (0.1 mM) in 2:1 molar ratio and the pH adjusted to 7.6. NaHSe and 
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(GS)2AsOH were mixed in a 1:1 (V/V) ratio to bring the final pH to 8.5. The compound 
was purified by passage through G10 column (30 cm-column) under strictly anaerobic 
conditions. An aliquot of each fraction was exposed to the ambient air to allow the 
detection of Se-containing eluates. Pure [(GS)2AsSe]- was recovered by pooling the Se-
containing fractions after gel filtration. (Gailer, J. et al., 2002) 
 
 
2.2- Cultivation of Keratinocytes 
2.2.1- Culture 
A keratinocyte cell line, HaCaT (Kind gift of Dr. Norbert Fusenig, Institute of 
Biochemistry, Cancer Research Center, Heidelberg, Germany), was cultured in 
Dulbecco’s modification of Eagle’s medium 1X (DMEM) with L-Glutamine and 4.5 g/l 
glucose supplemented with 10 % fetal bovine serum (FBS), 10,000 µg/ml streptomycin, 
and 10,000 IU/ml penicillin (Mediatech, Inc.).  The cells were incubated at 37 °C with   
5 % carbon dioxide to maintain proper pH. The culture was collected treating the cells 
with 0.05 % EDTA- Dulbecco’s Phosphate Buffered Saline (DPBS) without 
calcium/magnesium (Ca/Mg), then trypsin and transferring into a centrifuge tube as 




2.2.2- Culture in basal medium 
Due to the presence of selenoprotein P in the serum along with undefined forms 
of Se, we also cultured the keratinocytes in defined keratinocyte medium with L-
Glutamine and growth supplement (Gibco, Grand Island, New York). These cultures 




2.2.3- Long term arsenite treatment 
At 3-4 days post-confluence, the cells were split at a 1:5 ratio and the medium 
changed the next day. To the fresh medium was added 0.5 and 1 µM sodium arsenite (in 
triplicate) along with untreated control cultures. Images of the cultures were taken daily 
using an inverted microscope to document any morphology changes. The cells were then 
washed with DMEM then DPBS with Ca/Mg by centrifugation and the cell pellet was 
resuspended in lysis buffer for further sonication. Lysis buffer contained 50mM Tricine 
pH 8.0, 0.1 mM Benzamidine, 0.5mM EDTA and 1mM DTT. 
The crude cell lysate was clarified by centrifugation at 13000 x g for 10 minutes. 
This crude cell extract was used for further determination of enzyme activities or 




2.2.4- Short term arsenite treatment 
At confluency, the cells were treated with 2 µM sodium arsenite for 4 days. 
Untreated cells served as controls. Every 24 hours, control and treated cells were 
harvested as described in the previous section and the cell pellet stored at -20 °C until 
needed for further analysis. 
 
 
2.2.5- Short term arsenite treatment of cells grown in defined medium 
To determine the involvement of other selenoproteins in the FBS as Se source, the 
cells were grown in defined keratinocyte medium (Basal medium) for 72 hours, split 
(1:2), then treated the next day with 2 and 4 µM sodium arsenite for another 72-hour 




2.2.6- MTT Cell Proliferation Assay  
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay 
provides a simple method for determination of cell number using standard microplate 
absorbance reader. This assay was developed by Mossman (Mossman, T., 1983) and 
involves the conversion of the water soluble MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
 27
diphenyltetrazolium bromide) to an insoluble formazan ( Liu, Y. et al., 1997; Berridge, 
M.V., Tan, A.S. 1993; Vistica, D.T. et al., 1991). The formazan is then solubilized, and 
the concentration determined by optical density at 570 nm. 
Assay Protocol 
HaCaT cells were cultured in 96-well plates (0.31 cm2 growth surface, 340 µl 
volume) in defined medium which contains 10 nM sodium selenite (ICN Biomedicals, 
Inc., Aurora, OH) for 24 hours and treated with increasing concentrations of  sodium 
arsenite (0, 3, 6, 10, 12, 14 and 16 µM in triplicates) for another 24-hour period. A subset 
of cultures was supplemented with 40 nM and 90 nM sodium selenite to reach a final 
concentration of 50 and 100 nM. 
A 12 mM  MTT (Amresco, Solon, OH) stock solution in sterile PBS pH 7.4 was 
made and stored at 4°C protected from light (for four weeks maximum). MTT was added 
(10 µl) to each well (96-well plate) to obtain a final concentration of 1.2 mM. A negative 
control of 10 µl of the MTT stock solution added to 100 µl of medium alone was 
included. The culture was then incubated at 37 °C for 2-4 hours. After incubation of the 
cells with MTT, as described above, a solution of 10 % SDS- 0.01 M HCl (100 µl) was 
added to each well as a solubilizing agent to dissolve the formazan (Carmichael, J. et al., 
1987) and mixed thoroughly with the pipette. The culture was then incubated at 37 °C for 
18 hours. The samples were mixed again and absorbance read at 570 nm using a 
SpectraMax 190 microplate reader (Molecular Devices Corporation, Sunnyvale, CA) or 




 2.3- Bradford Assay 
2.3.1- Principle 
The Bradford Assay was used for determining protein content of cell extracts or 
purified protein concentrations preparations. The assay is based on the observation that 
the absorbance maximum for an acidic solution of Coomassie Brilliant Blue G-250 shifts 
from 465 nm to 595 nm when binding to protein occurs. Both hydrophobic and ionic 
interactions stabilize the anionic form of the dye, causing a visible color change 
(Bradford, M. M.  (1976) Anal. Biochem. 72, 248). 
Bradford reagent: Coomassie Brilliant Blue G-250 (100 mg) was dissolved in 50 
ml 95 % ethanol, added 100 ml 85 % (w/v) phosphoric acid. The solution was diluted to 
1 liter when the dye completely dissolved, and filtered through Whatman #1 paper. A 
standard curve of absorbance at 595 nm versus protein concentration was routinely 
prepared for protein assays using BSA as a standard.  
The spectrophotometer was warmed up for 15 min before use and the samples 
diluted with distilled water to an estimated concentration of 1 to 20 µg/ml. Standards 
containing a range of 1 to 2.5 µg protein (bovine serum albumin) to a volume of 200 µl 
were prepared. Dye reagent (1 ml) was added and incubated 5 min. Absorbance at 595 




2.4- Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
SDS-PAGE was used to analyze the protein content of cell lysates and as the first 
step for immunoblot analysis of selenoenzymes. A 12 % polyacrylamide gel was used to 
resolve the proteins and 5 % gel to stack the extract in the lanes. The 4X separating gel 
buffer consists of 0.4 % SDS, 1.5 M Tris-HCl, pH 8.8. The 4X stacking gel buffer 
consists of 0.4 % SDS, 0.5 M Tris-HCl, pH 6.8. Our 10ml separating gel contained 2.5 
ml 4X separating buffer, 4.0ml 30 % acrylamide stock solution (29.2 % acrylamide,  3.5 
ml distilled water, 100 µl 10 % ammonium persulfate, and 10 µl TEMED. The 5 ml 
stacking gel contained 1.25 ml 4X stacking buffer, 0.83 ml (4 %) 30 % acrylamide stock 
solution,  2.9 ml distilled water, 50 µl 10 % ammonium persulfate and 5µl TEMED. The 
running buffer contained 25 mM Tris-HCl, 192 mM Glycine and 0.1 % w/v SDS. The 
samples were denatured by addition of 2X SDS-PAGE sample buffer (4X stacking gel 
buffer, 20 % glycerol, 4 % SDS, 31 mg/ml DTT) and the samples were boiled for 5 
minutes, followed by a 10-minute cooling at room temperature. Proteins were subjected 
to electrophoresis for 55 minutes at 150 volts.    
 
 
2.5- Western blot analysis 
Western blot were used to analyze the level of glutathione peroxidase (Gpx) and 
thioredoxin reductase (TrxR) proteins in the control and arsenite-treated samples. Thirty 
to 50 µg of protein extract ( varied in alternate experiments) was analyzed using 12 % 
SDS-PAGE, and subsequently transferred (transfer buffer 25 mM Tris-HCl, 192 mM 
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Glycine, 20 % v/v Methanol) onto a hydrophobic polyvinylidene fluoride (PVDF) 
membrane. The transfers were routinely performed overnight at 30 volts for optimal 
transfer of protein. The membrane was incubated in a 2 % bovine serum albumin solution 
(BSA) in TBS-Tween for 1 hour to block the membrane. The primary antibodies used at 
1/1000 dilution were polyclonal sheep anti-Gpx (company) or rabbit anti-TrxR 
(Stadtman, T.C., NIH). The secondary antibodies (1/1000 dilution) were rabbit anti-
sheep, and goat anti-rabbit each conjugated with alkaline phosphatase. The required 
reagents were Tris buffered saline with Tween-20 (TBS-T ) 20 mM Tris-HCl pH 7.2, 150 
mM NaCl, 0.01 % Tween-20), 2 % BSA in TBS-T and phosphatase alkaline buffer (0.1 
M Tris, 100 mM NaCl, 5 mM MgCl pH 9.5). We used a chromogenic detection system 
with nitro blue tetrazolium (NBT, 5mg/ml of 70 % Dimethyl Formamide, DMF) and 5-
bromo-4-chloro-3-indolyl phosphate (BCIP, 5 mg/ml of 100 % DMF) in alkaline 
phosphatase buffer to visualize the presence of bound secondary antibody. 
 
 
2.6- Selenium (75Se) labeling of selenoproteins 
HaCaT cells were cultured in DMEM with 10 % FBS in the presence of arsenite 
(200 nM to 8 µM). The keratinocytes were radiolabeled with 100 µl 75Se 
(approximatively 10 µCi) in 10 nM sodium selenite for 8 hours. Cells were then 
harvested, lysed by sonication, clarified by centrifugation (13,000 x g) and 28 µg of cell 
extract was loaded in each lane (determined by Bradford assay with BSA as standard). 
The gel was stained with Coomassie blue G250 for 1hour, then destained for 30-60 min 
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with a solution composed of 50 % methanol and 10 % acetic acid. After drying the gel 
overnight (DryEase Minigel Drying System from Invitrogen, Carlsbad, CA), and 
incubation for 3 days in the phosphor storage cassette, the radiolabeled proteins were 
visualized using a Storm 840 phosphorimager (Molecular Dynamics/ Amersham 
BioSciences). The storage cassette screen retains energy from beta particles, X-rays, and 
gamma rays. Upon laser-induced stimulation, light is emitted from the storage phosphor 
screen in proportion to the amount of radioactivity in the sample. 75Se isotope 
incorporation was also determined using a Perkin-Elmer 1470 Gamma counter from Life 
Sciences and quantitatively compared to total protein concentration to determine the 
efficiency of Se incorporation (cpm/µg of extract). 
 
 
2.7- Sulfur (35S) labeling 
HaCaT keratinocytes were grown in 12-well plates (3.66 cm2 growth surface,  
6.30 ml volume), and then treated with increasing concentrations of arsenite from  
200 nM to 6 µM for 4 hours. Two µl (29 µCi) of  35S (Redivue Pro-Mix 35S, Amersham 
BioSciences, San Francisco, CA) in the form of Cys and Met in 2 ml DMEM (low Cys 
and Met) was used to label newly synthesized proteins during arsenite treatment. After 
the 4-hour period, the cells were harvested, lysed and a crude cell extract made as stated 
previously in section 2.2.3. To determine the radioactivity (35S) in each extract, 5 µl of 
sample was added to 3.5 ml of Opti-Fluor scintillation liquid (PerkinElmer Life Sciences, 
Boston, Massachusetts) and read using a TriCarb 2900TR liquid scintillation analyzer 
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(Packard BioScience, Boston, Massachusetts). Equal concentration of protein (1 µg) was 
analyzed by SDS-PAGE. The 12 % gel was then dried immediately without staining. 
After drying and incubation for 3 days in the phosphor storage cassette, sulfur 
incorporation into protein was analyzed by a phosphorimager (Amersham BioSciences).  
 
 
2.8- Haemophilus inflenzae (H. i.) SPS overexpression  
A selenocysteine-containing SPS was overexpressed using E. coli BL21 strain 
that contained the plasmid coding for HISPS (pET3aHIselD). The plasmid was obtained 
as a generous gift from T.C. Stadtman (NHLBI, NIH, Bethesda, Maryland). Cells were 
grown aerobically in 2.8-liter flasks containing Luria broth (10 g tryptone, 5 g yeast 
extract, 5 g NaCl /L) supplemented with 0.3 % dextrose, 10 mg/L chloramphenicol and 
100 mg/L ampicillin. Flasks were incubated at 37 °C with vigorous shaking (180 rpm) 
until the optical density (OD) reached 0.7 at 600 nm. Expression of HISPS was then 
induced with Isopropyl-ß-D-thiogalactopyranoside (IPTG) and cultured at room 
temperature for 24 hours. OD readings and samples were taken at 2 hour intervals for 6 
hours and then overnight. Cells were harvested using a SLA 1500 rotor (Sorvall) 
centrifuge, 5,000 rpm at 4 °C for 10 minutes. Cell pellets were washed in buffer A (50 
mM Tris, 0.5 mM EDTA, 1 mM DTT), then lysed in lysis buffer (50mM Tricine pH 8, 
0.1 mM Benzamidine, 0.5 mM EDTA, 1mM  DTT) by sonication and the cell debris 




2.9- Haemophilus inflenzae (H. i.) SPS purification 
The purification process was done in 3 steps in the following order: Phenyl 
Sepharose chromatography, Diethylaminoethyl Fast Flow anion-exchange 
chromatography (DEAE) and then gel filtration chromatography (Sephacryl S-200) 
(Amersham BioSciences). 
Phenyl Sepharose chromatography 
All the solvents and buffers were degassed prior to use. The column was 
prewashed with 3 column volumes distilled water, followed by passage of 2 column 
volumes of buffer A. The column was then equilibrated with buffer A containing 1.5 mM 
ammonium sulfate and the sample loaded. A 300 ml gradient of ammonium sulfate (1.5 
mM-0 mM) was made with the PACE gradient maker (Bioworld, Dublin, Ohio) to elute 
the bound proteins. After a thorough wash with buffer A, the SPS-containing fractions 
were eluted with 4 column volumes of 30 % ethylene glycol (EG) in buffer A. Fractions 
(5 ml were collected and the presence of HISPS was assessed by western blot using 
polyclonal antibody raised against the E. coli SPS. The fractions containing SPS were 
pooled concentrated down to a smaller volume, then dialyzed twice overnight (against 1L 
of dialysis buffer) to remove the ethylene glycol before loading on a DEAE column. The 
dialysis buffer contained 0.5 mM Tris pH 7.5, 0.5 mM EDTA, 0.1 mM DTT. 
DEAE chromatography 
The dialyzed pooled sample from phenyl chromatography was then applied to a 
pre-equilibrated DEAE column. A 0.0-0.5 M potassium chloride (KCl) gradient was used 
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to elute bound proteins. The column was washed with buffer A containing 0.5 M KCl 
until no significant protein eluted from the column (by Bradford assay, see section 2.3). 
The column was cleared of any remnant protein by passage of 2 M sodium chloride 
(NaCl). Fractions (5 ml each) were collected during the 0.0-0.5 M KCl gradient and the 
presence of Hi SPS was determined by SDS-PAGE and western blot. The fractions 
containing Hi SPS were pooled and concentrated down to a smaller volume. No dialysis 
was necessary because the salt concentration in the sample was ideal for the next step of 
the purification process. 
Gel filtration chromatography 
The column was slowly washed overnight with a large volume (2 liters) of 
distilled water and equilibrated with buffer A containing 0.3 M KCl for 6 hours. The 
sample was then loaded manually onto the column close to the column medium. Once the 
solvent entered the column, being careful not to perturb the column, the buffer was then 
pumped through the column at a slow rate (approximatively 1.5 ml/min). Fractions were 
collected and the purity of HISPS assessed by SDS-PAGE. The sample (110 mg) was 
determined to be greater than 98 % pure based on SDS-PAGE analysis (Coomassie Blue 
staining). The final concentration was determined by absorbance reading at 280 nm in 6 
M Guanidinium, HCl in 25 mM Tris pH 7.8 using the predicted molar extinction 




2.10- Sample preparation for X-ray atomic absorption (XAS) 
A sample of pure HISPS was prepared for XAS analysis by overnight dialysis 
against 50 % glycerol in 50 mM Tris, then concentrated to 35 mg/ml protein. A 625 µM 
SPS in 50 % glycerol in 50 mM Tris was sent to Dr. Robert Scott at the Department of 
Chemistry, University of Georgia, Athens, Georgia for Se XAS analysis. 
 
 






Thioredoxin-S2 + DTNB TNB + Thioredoxin - (SH)2
Thioredoxin Reductase
NADPH
DTNB = 5,5'-Dithio-bis(2-Nitrobenzoic Acid)
TNB = 5-Thio-2-Nitrobenzoic Acid
NADPH = Nicotinamide Adenine Dinucleotide Phosphate, Reduced Form 
 
This assay is a continuous spectrophotometric rate determination. Thioredoxin 
reductase activity was measured as NADPH-dependent 5,5’-dithio-bis-(2-nitrobenzoic 
acid) (DTNB) reduction The one ml assay mixture contained 100 mM potassium 
phosphate buffer pH 7.0, 0.2 mM NADPH, 2.5 mM DTNB and 10 mM EDTA. The 
spectrophotometer was blanked with the above mixture then the assay started with 
 36
addition of 200 µg of protein extract (Gorlatov, S. N., Stadtman, T. C., 1998). A 
spectrum was recorded every 15 seconds for 22 minutes, 2 minutes before addition of the 
extract and 20 minutes after to determine the baseline rate of DTNB reduction and 




Gpx activity was determined using a previously described coupled assay with 
glutathione reductase with slight modifications (Lawrence, R.A., Burk, R.F., 1976). The 
assay buffer contained 100 mM potassium phosphate buffer pH 7.0, 0.2 mM NADPH, 
0.1 mM EDTA, 1 mM GSH, 240 mU glutathione reductase, 50 µg of protein extract that 
was used to blank the cuvette. The oxidation of NADPH by hydroperoxides was followed 
spectrophotometrically at 340 nm after addition of 250 µM hydrogen peroxide (H2O2) to 
the reaction mixture. A spectrum was recorded every 15 seconds for 12 min., 2 min. 
before addition of H2O2 and 10 minutes after. Initial rate of reduction of hydroperoxides 





CHAPTER THREE: RESULTS 
3.1- Inhibition of Selenophosphate synthetase  
 Exposure to arsenic by ingestion of contaminated drinking water is linked to skin, lung, 
kidney, liver and bladder cancer. The toxicity of trivalent arsenicals such as arsenite is related to 
their high reactivity with vicinal dithiols. Arsenite is known to bind to vicinal sulfhydryl groups 
on small compounds such as glutathione (GSH). It was shown that E. coli SPS contains seven 
Cys residues and two of them are located at the amino-terminal region forming a CXC motif. 
Such motif with vicinal dithiols could represent a binding site for trivalent arsenicals which 
makes SPS an interesting selenoprotein to study. In addition, SPS is a key enzyme in the 
selenoprotein biosynthesis pathway. SPS catalyzes the activation of selenide into 
selenophosphate in the presence of ATP, the first step of the pathway. 
To determine if sodium arsenite inhibits SPS activity in vitro with sodium selenide as a 
substrate, we have spectrophotometrically followed the effect of arsenite on SPS activity. The 
experiment was done under strictly anaerobic conditions. Arsenite does not inhibit the coupled 
reaction, as we have determined that up to 100 µM arsenite does not affect PNP reaction with 
MESG (data not shown). Addition of arsenite resulted in the inhibition of SPS activity (Figure 
7). Figure 7 illustrate that arsenite inhibits the NaHSe-dependent hydrolysis of ATP in a 
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Figure 7: Initial rate plot of a typical SPS assay with 0, 10, 17.5, 25 µM arsenite. Each point 
represents at least three independent enzyme assays.   
 
To determine whether this inhibition is competitive with NaHSe, we analyzed SPS 
activity at several concentrations of NaHSe while varying the concentration of arsenite. A 
summary of these activities is shown in a double-reciprocal plot of SPS activity versus [NaHSe] 
in figure 8. Inhibition of SPS by arsenite is competitive. A plot of the slopes of the lines in figure 
8 versus arsenite concentration revealed an apparent Ki of 3 µM. This is roughly half the apparent 
Km we have measured for SPS (7.8 µM), demonstrating that arsenite or other trivalent arsenicals 
could be relevant inhibitors in vivo. 
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Our results are consistent with previous findings (Km of 7.3 µM for NaHSe) using 14C-
TLC, a different method. (Veres, Z., 1994). 
 
1/[S]












1/[S] vs 0uM As 
1/[S] vs 10uM As 
1/[S] vs 17.5uM As 
1/[S] vs 25uM As 
 
 
Figure 8: Double reciprocal plot to analyze the type of inhibition of SPS by arsenite. Each point 
represents at least three independent enzyme assays.   
 
Arsenic binds to macromolecules such as glutathione upon entry into the cell (Winski, 
S.L, Carter, D.E., 1995). 
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Hence, we have tested the possibility that the glutathiolated derivative, (GS)2AsOH being a 
trivalent in vivo form of arsenic, acts as SPS inhibitor. As shown on figure 9 (GS)2AsOH  also 
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Figure 9: Plot of Activity (nmoles.min-1.mg-1) versus (GS)2AsOH concentration. SPS was 
anaerobically incubated with (GS)2AsOH and the activity was analyzed on a spectrophotometer. 
The change in absorbance at 365 nm was recorded. Clearly, (GS)2AsOH, at the concentrations 




DNA sequence analysis of SelD gene showed that human SPS 2 contains a SeCys residue 
at the N terminal region proximal to a Cys residue (Figure 3. Conserved N-terminal domain 
sequence). Since SPS 2 contains a UXC motif, it would be best to test the assays using a human 
SPS or the closest form to the human SPS. However, the expression of human SPS1 and SPS2 in 
E. coli has been problematic (Tamura, T., unpublished data). Therefore, we attempted to express 
and purify a model enzyme, SPS from Haemophilus influenzae which contains a SeCys.  
 
 
3.2- Attempt to purify active HI SPS 
Haemophilus influenzae SPS which contains a SeCys (Figure 3) has been expressed and 
purified in a previous study (Lacourciere, G.M., Stadtman T.C., 1999). Because HISPS 
resembles the human SPS2, we decided to express and purify this as a model for human SPS2. 
HISPS was expressed in E. coli and purified in three steps in the following order: Phenyl 
Sepharose chromatography, DEAE Fast Flow anion-exchange chromatography and finally gel 
filtration chromatography. During each step of the purification, we used SDS-PAGE analysis and 
western blots to determine the fractions to be pooled. Figure 10 shows fractions from the gel 



















Figure 10: SDS-PAGE analysis of fractions collected after gel filtration chromatography. On 
lanes 1, 10, purified E.coli SPS was used as a marker. Lanes 3-9 show the degree of purity of 
HISPS in each fraction. We obtained 110 mg of about 98 % pure HISPS. 
 
Activity of the purified HI SPS was tested using the same coupled assay that was used to 
follow NaHSe-dependent activity of E.coli SPS. We did not detect any activity with the purified 
HISPS. To determine whether or not a SeCys residue is present in this purified HISPS, we 
prepared the protein (HISPS) for X-ray absorption analysis. XAS analysis carried out in the 
laboratory of Dr. Robert Scott (University of Georgia) showed that HISPS preparation did not 
contain appreciable quantities of Se. We are unsure why this preparation does not contain 
selenium and has no activity. 
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We demonstrated that arsenite inhibits SPS and that the inhibition is competitive to 
selenide, the substrate. To investigate our hypothesis which states that a possible mechanism of 
arsenic toxicity might be the inhibition of selenium bioavailability, we decided to follow 
selenium incorporation into selenoproteins.  
 
 
3.3- Selenium 75 (75Se) labeling 
It has been shown that trivalent arsenicals induce the production of ROS in Chinese 
Ovary Cells (Wang, T.S. et al., 1996), acute promyelocytic leukemia cells (Jing, Y. et al., 1999), 
and human keratinocyte cells (HaCaT) (Shi, H., et al., 2004). Based on our hypothesis, this 
increase is due to a decrease of the level of active selenoenzymes in the cell.  HaCaT cell line is a 
spontaneously transformed human epithelial cell line from adult skin with unlimited growth 
potential; it is similar to normal skin cells. 
To determine if arsenite has an effect an effect on Se incorporation, we labeled an 
arsenite-treated culture of HaCat cells with the radioactive form of selenium (sodium selenite), 
75Se. To trace Se incorporation into selenoprotein, the cells were labeled with 10 µCi 75Se 
radioisotope for 8 hours. Cells were then harvested, washed and lysed by sonication as described 
in the “Materials and Methods” section. Equal concentrations of cytosolic protein were analyzed 
by SDS-PAGE (Figure 11). Figure12 shows a decrease in Se incorporation in a concentration-
dependent manner. Arsenite treatment of HaCaT cells prevents incorporation of Se into 
selenoproteins in a concentration-dependent manner. The higher the arsenite concentration, the 
lower the radioactivity detected, hence, arsenite affects Se incorporation into the cell. 
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Based on this finding, we conclude that trivalent arsenicals affect the bioavailability of Se 
thus leading to a decrease in selenoproteins at a cellular level. To be sure the observed effects are 
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Figure 11: SDS-PAGE of 75 Selenium  (75Se-Selenite) radiolabeled keratinocytes treated with 
sodium arsenite. The keratinocytes were treated with increasing concentrations of arsenite from 
200nM to 6µM for 8 hours. Protein extracts were resolved on 12% SDS-PAGE and the labeled 
proteins were analyzed using a phosphorimager. Lanes 1, 2, 10, 11: controls. Lanes 3, 4: 200 nM 
Arsenite. Lanes 5, 6: 500 nM Arsenite. Lanes 7, 8: 1 µM Arsenite. Lanes 9, 12: 2 µM Arsenite. 
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Figure 12: Arsenite treatment prevents selenium incorporation into selenoproteins. The level of 





3.4- Arsenite treatment of keratinocytes does not affect total protein synthesis 
Arsenite treatment of HaCaT cell culture lead to a decrease in the incorporation of Se into 
selenoproteins. To determine whether the effect of arsenite on HaCat cells is specific to Se 
incorporation or extended to total protein synthesis, we treated the cells with different 
concentrations of arsenite and radiolabeled them with Sulfur 35 mixture of methionine and 
cysteine (35S) for 8 hours to follow new protein synthesis. Cells were harvested and lysed by 
sonication. As indicated by the figure 13 and the graph on figure 14, arsenite has no effect on 
total protein synthesis. This confirms that the effect of arsenite is specific to incorporation of Se 
into selenoproteins. Although good labeling of cellular proteins was demonstrated using 35S-Met-
Cys mix, we also determine whether arsenite was affecting proliferation of the cells under these 

























Figure 13: SDS-PAGE after 35 Sulfur (35S) labeling of HaCaT keratinocytes. The keratinocytes 
were treated with increasing concentrations of arsenite from 200 nM to 6 µM for 4 hours. Newly 
synthesized proteins were labeled during arsenite treatment by 35S methionine/cysteine. Protein 
extracts were resolved on 12% SDS-PAGE and the gel was developed using a phosphorimager.  
Lane1: control - No arsenite added. Lane 2: 200 nM Arsenite. Lane 3: 500 nM Arsenite. Lane 4: 






































Figure 14: Measure of Sulfur incorporated into Met/Cys during new protein synthesis. HaCaT 
culture was labeled with 35S, and then treated with increasing concentrations of sodium arsenite. 







3.5- Arsenite does not affect keratinocyte proliferation    
The previous experiments showed that treatment of HaCaT cells using micromolar 
concentrations of arsenite for a relatively short period of time does not affect protein synthesis.  
To confirm the viability of the keratinocytes in the presence of arsenite at these 
concentrations (up to 16 µM), we did an MTT cell proliferation assay. The keratinocytes (4000 
cells per well cultured as a monolayer) were incubated with arsenite for 24 hours prior to MTT 
treatment. The results presented in figure 15 show a slight decrease in proliferation with 3 and    
6 µM arsenite followed by a recovery with 12 µM. At 14 µM, the cell growth becomes stable. 
Overall, the cell proliferation was not significantly affected by the concentrations of arsenite 
used.  
In conclusion, these labeling experiments and cell proliferation assay confirmed that 
although arsenite does not affect keratinocytes proliferation in DMEM, it inhibits incorporation 
of radiolabeled selenium. As a control then we decided to grow the cells in defined keratinocyte 
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Figure 15: MTT Cell Proliferation Assay in DMEM. The keratinocytes seeded at 4000 cells per 
well were cultured in a 96-well plate for 24 hours and subsequently exposed to increasing 
concentrations of sodium arsenite for an additional 24 hours. After addition of MTT (4 hours 
incubation), followed by a solution of SDS-HCl for an overnight incubation, the absorbance was 




In DMEM supplemented with serum, other sources of selenium such as selenoprotein P 
are available to the cell whereas in the defined keratinocyte medium, only 10 nM of sodium 
selenite is present. The composition of this defined medium will allow us to control the Se 
supply to the cell in order to detect any effect of higher concentrations of Se in an arsenite-
treated keratinocyte culture. To determine the effect of selenite on the keratinocytes proliferation, 
the cells were grown in defined medium. A subculture was supplemented with 50 nM and       
100 nM sodium selenite for 24 hours before exposure to the same concentrations of arsenite as 
reported above. Clearly, arsenite slows cell growth in defined medium as shown by figure 16A. 
Here the proliferation was partially recovered after addition of 50 nM selenite (Figure 16B) and 
completely with 100 nM (Figure 16C). 
 Using a defined keratinocyte medium with known concentrations of available selenite, 
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Figure 16: Effect of arsenite on cell proliferation. The keratinocytes were grown in defined 
medium containing 10, 50 and 100 nM sodium selenite for 24 hours and then treated with 
increasing concentrations of sodium arsenite for an additional 24-hour period. After addition of 
MTT and SDS-HCl the absorbance was read at 570 nm. The percent cell proliferation was 
calculated based on the untreated (no arsenite) sample. With 50 and 100 nM selenite, there is a 
protective effect of selenite against arsenite. 
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3.6- Long term arsenite treatment of HaCaT with low levels of sodium arsenite 
Epidemiological studies have shown that chronic exposure to arsenic contributes to skin, 
lung, and bladder cancer (Smith, A.H., 1998, Schwartz, R.A., 1997, Yeh, S., 1973). There is a 
link between high levels of arsenite in drinking water and cancer. Also, studies demonstrated 
high As/Se ratio in Black-Foot Disease patients (Wang, C.T., 1993). Glutathione peroxidase 
functions to neutralize peroxides and oxidized membrane lipids. Thioredoxin reductase is a key 
enzyme in the control of cell proliferation and redox balance. Thus active Gpx and TrxR are 
essential to the cell’s defense against reactive oxygen species. To mimic the long term exposure 
to trivalent arsenicals using a cell culture model, we cultured HaCaT cells in DMEM 
continuously for 6 weeks in the constant presence of sodium arsenite and then determined the 
effect of arsenite on the cells. After 6 weeks of cell culture (4 passages) without arsenite and with 
0.5 and 1 µM arsenite the cells were harvested and disrupted by sonication. The cell extract was 
clarified by centrifugation. The protein extract was then tested for Gpx and TrxR level by 
western blot and enzyme activity by spectrophotometry.  
The long term arsenite treatment under our conditions did not show any morphological 
effects on the cells (Figure 17). The western blots show no change in the levels of Gpx and TrxR 
levels as presented on figure 18. Glutathione peroxidase and thioredoxin reductase, two 
important antioxidant selenoproteins in the cell extract were tested for activity. The activity 
assays confirmed the constant level of protein previously observed on figure 18. There was no 




























Figure 17: HaCaT treated with 0.5 and 1 µM sodium arsenite after six weeks and four passages. 



























Figure 18: Immunoblot analyses of TrxR (A) and Gpx (B) levels after long term exposure (6 
weeks) of keratinocytes (HaCaT) to 0.5 and 1 µM of sodium arsenite. A1-3: Control- No 














































Passage 1 Passage 3
Passage 4
Passage 2
0             0.5            1.0
Arsenite Concentration  (µM)  
0              0.5             1.0


































Figure 19: Gpx Activity Assay on long term arsenite-treated HaCaT culture. The cells were 
treated with 0.5 and 1 µM of sodium arsenite for 6 weeks (4 Passages) and then harvested. The 
cell extract was used (50 µg) to test Gpx activity by spectrophotometry. The change in 
absorbance at 340 nm was recorded and the activity calculated. A long term arsenite treatment 
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Figure 20: TrxR Activity Assay on long term arsenite-treated HaCaT culture. The keratinocytes 
were treated with 0.5 and 1 µM of sodium arsenite for 6 weeks (4 Passages) and then harvested. 
The cell extract was used (200 µg) to test trxR activity by spectrophotometry. The change in 
absorbance at 340 nm was recorded and the activity calculated. TrxR activity decreased with      
1 µM the first 2 weeks of culture, then with 0.5 µM the following weeks to end up increasing at 
the last week of culture. 
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In summary, our results showed that arsenite induced no morphological changes of the 
keratinocytes after continuous culture in arsenite-containing medium. Also, arsenite did not 
affect Gpx and TrxR at the protein level as well as the activity level.  
In DMEM supplemented with fetal bovine serum, several selenium sources are available 
to the cell. The keratinocytes might be using an alternate pathway that consumes a different 
selenium source to produce normal level of selenoproteins. This led us to investigate whether or 




3.7- Short term arsenite treatment in DMEM 
To determine if higher concentrations have a more significant effect on selenoproteins, 
we cultured and treated the keratinocytes with 2 µM arsenite in DMEM for 96 hours. At each 24-
time point, we harvested untreated and treated cells. After 4 days, we analyzed Gpx and TrxR 
levels by western blot. Figure 21 demonstrates that short term arsenite treatment of keratinocytes 
has still no effect on Gpx and TrxR levels.  
Glutathione peroxidase and thioredoxin reductase activity assay also did not show any 
change compared to the untreated control cells (Figure 22). Although there is a downward trend 
of Gpx activity at day 2, the decrease is not significant. Overall short term arsenite treatment 
does not affect Gpx activity. Hence, we decided to control and limit the Se source by using a 
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Figure 21: Analyses of Gpx (A) and TrxR (B) levels after short term exposure (4 days) of 
keratinocytes (HaCaT) to 2 µM of sodium arsenite. Protein extracts were resolved on 12% SDS-
PAGE and analyzed by immunoblot using Gpx and TrxR antibodies. Arsenite treatment had no 
effect on Gpx and TrxR levels under the studied conditions. C1-4: Control- No arsenite. D1-4: 










































Figure 22: Gpx Activity Assay on short term arsenite-treated HaCaT culture. The keratinocytes 
were grown in DMEM-10 % FBS then treated with 2 µM of sodium arsenite for four days and 
then harvested. The cell extract was used (50 µg) to test Gpx activity by spectrophotometry. The 





3.8- Short term arsenite treatment in defined keratinocyte medium 
The keratinocytes have, in DMEM, all the nutrients necessary to grow. In consequence, 
the cells might use an alternate selenium supply present in serum. The Se depletion due to 
arsenite treatment seen in radioisotope labeling may be compensated by selenoprotein P in the 
serum, and this may bypass the effect of arsenicals. 
To rule out the involvement of selenoprotein P in the FBS as a selenium source, a basal 
serum-free medium with trace of sodium selenite (10 nM) was used to conduct another short 
term experiment with 2 µM of arsenite or 4 µM for 72 hours.  
Our results presented in figure 23 showed that no change occurred in the cell morphology 
or cell density during the three-day treatment with 2 µM of arsenite. The western blot analysis 
(Figure 24) confirmed the results by showing steady Gpx and TrxR levels. This led us to increase 
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Figure 23: Keratinocytes culture in defined medium. The cells were treated with 2 µM sodium 
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Figure 24: Analyses of Gpx (A) and TrxR (B) levels after short term arsenite treatment. The 
keratinocytes (HaCaT) were cultured in defined medium, and then exposed to sodium arsenite 
for 3 days. Protein extracts were resolved on 12% SDS-PAGE and analyzed by immunoblot 
using Gpx and TrxR antibodies. C1-2: Control- No arsenite. D1-3: 2 µM sodium arsenite. D1: 




3.9- Short term arsenite treatment in defined medium- 4 µM arsenite 
Four micromolar arsenite would not be considered a physiologically relevant 
concentration but we decided to use such amount in order to trigger enough cell response to 
study the effect of arsenite on HaCaT. 
Our results showed no change in cell culture (Figure 25) which was confirmed by the 
western blot analysis of two proteins marker of oxidative stress, Gpx and TrxR. Their level 
stayed steady through the whole experiment (72 hours) (Figure 26). Also, 4 µM of sodium 





































Figure 25: Keratinocytes culture in defined medium. The cells were treated with 4 µM sodium 
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Figure 26: Western Blot analyses of Gpx (A) and TrxR (B) levels after short term arsenite 
treatment (4 µM). The keratinocytes (HaCaT) were cultured in defined medium, and then 
exposed to sodium arsenite for 3 days. C: Control- No arsenite. D1-3: 4µM sodium arsenite. D1: 














































Figure 27: Gpx Activity Assay on short term arsenite-treated HaCaT culture. The keratinocytes 
were grown in defined medium then treated with 4 µM of sodium arsenite for four days and then 
harvested. Fifty µg of the cell extract was used to test Gpx activity. The change in absorbance at 






CHAPTER FOUR: DISCUSSION  
4.1-Spectrophotometric assay for SPS 
Inorganic selenium is inserted into proteins as the rare 21st amino acid selenocysteine 
that is essential for the catalytic function of selenoenzymes. It has been shown that selenium is 
required in several mammalian enzymes with roles in defense against reactive oxidative species 
(Carlson, B.A., et al., 2004). Selenoproteins such as Gpx, TrxR and SPS with known enzymatic 
functions contain selenocysteine in their catalytic center (Tamura, T. , Stadtman, T. C., 1996, 
(Arner, E. S., Holmgren, A., 2000, Lee, S. R. et al., 2000, Flohe, L. et al, 1973, Brigelius-Flohe, 
R., 1999, Chambers, I. et al. 1986, Kryukov, G. V. et al. 2002). Selenoproteins incorporate 
SeCys cotranslationnally into the polypeptide chain by a complex mechanism (Low, S.C. et al., 
1996) that is only recently being better understood. 
 SPS is required for the synthesis of selenoproteins in both prokaryotes and eukaryotes. 
SPS uses a reduced form of selenium (NaHSe in the in vitro assay) and ATP to generate 
selenophosphate. Previous assays for SPS (Veres, Z., et al, 1992) were hindered by the use of 
[14C] ATP and thin layer chromatography (TLC). The SPS assay is a sensitive coupled 
enzymatic assay described by Webb (Webb, M.R., 1992) for detecting inorganic phosphate and 
to monitor the kinetics of phosphate release by selenophosphate synthetase in solution through 
formation of a chromophoric product. We have incorporated this coupled assay to study the 
kinetics of SPS. The reagent used in this assay are easily oxidized by air, hence the importance 
of working under strictly anaerobic conditions. Veres’s group findings corroborated the above 
assertion. In their study of SPS activity, they were able to lower the Km for NaHSe from 46 µM 
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to 7.3 µM by maintaining strictly anaerobic conditions (Veres, Z., et al, 1994). [14C] ATP TLC 
assay measured the selenide-dependent formation of AMP from ATP after separation of 14C 
labeled nucleotides by TLC and required prolonged incubation time and higher levels of enzyme, 
hence the importance of developing an improved and sensitive spectrophotometric assay. The 
improvement of the method is based on the ability to measure initial rates (V0) more easily.  
 Using this coupled assay in our study, we have determined the apparent Km value for 
NaHSe as 7.8 µM. This is similar to previously reported value using a different method. Our 
spectrophotometric assay has proven to be more useful for initial rate analysis and may lead to a 
better understanding of other SPS enzymes such as human SPS 1 and 2 in future studies. 
 
 
4.2-Arsenite inhibits SPS 
Arsenic has been implicated as a contributing factor in carcinogenesis (Hughes, M. F., 2002). 
Biologically, the trivalent sodium arsenite is more carcinogenic than the pentavalent form 
sodium arsenate (Barrett, J.C. et al., 1989). Cultured mammalian cells have provided some 
possible mechanisms by which arsenic and arsenical compounds may exert a carcinogenic 
activity. Based on known interactions of As with vicinal dithiols and the fact that 
selenophosphate synthetase also contains a proximal cysteine motif (Figure 3), we have tested 
the possibility that arsenite and/or (GS)2AsOH (AsIII) would inhibit SPS. 
Arsenite, a trivalent arsenical known to bind to vicinal and proximal dithiols was found to 
inhibit E. coli SPS. Amino acid substitutions in a conserved N-terminal region by Kim et al. 
using site-directed mutagenesis have proven that Cys-17 is vital to the enzyme activity. They 
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reported a complete loss of SPS catalytic activity when Cys 17 and 19 were substituted to Ser 
residues (Kim, I.Y. et al., 1993). Although the structure of SPS has not been elucidated yet, 
based on sequence homology, Cys 17 and 19 are likely to be proximal in 3-dimensional space. 
Our study has shown that sodium arsenite clearly inhibits SPS activity in a concentration-
dependent manner (Figure 7). Kinetic analysis revealed a competitive inhibition with NaHSe 
with an apparent Ki of 3 µM likely involving Cys 17 and 19. Since the proximal cysteine motif 
has been previously postulated to be involved in selenium binding during catalysis, it seems 
likely that arsenite is also binding to this motif.  The present results give support to previous ones 
suggesting Se binding to the proximal cysteine motif in the conserved N-terminal region. In the 
light of our results, it is possible that a decrease in selenoprotein synthesis due to a decrease in 
SPS activity might be a molecular mechanism for arsenic-induced carcinogenesis. This 
hypothesis led us to the next series of experiments in a cell culture model system. 
 
 
4.3-Se incorporation into selenoprotein inhibited by arsenite 
 To determine whether arsenite has an effect on Se incorporation in vivo, we radiolabeled 
an arsenite-treated culture of HaCat cells with 75Se. Our results showed a decrease in Se 
incorporation (Figure 11) in a concentration-dependent manner after exposure to arsenite. The 
higher the concentration of arsenite, the lower the Se incorporated into the cells suggesting that 
arsenite may be decreasing selenium bioavailability. New selenoproteins synthesis is affected by 
arsenite. Such observation has been reported for the first might be due to the inhibitory effect of 
trivalent arsenical on SPS. Another possibility is the formation of As-Se bound compound in 
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vivo. In fact, previous studies in rabbit have shown that co-injection of As and Se results in the 
formation of [(GS)2AsSe]- which is excreted from the bile (Gailer, J. et al., 2002, Gailer, J., 
2002). 
Since Se incorporation was affected by arsenite, we decided to determine whether this 
effect is specific to selenoprotein synthesis or not. We labeled the keratinocytes with 35S 
radioisotope in order to follow total protein synthesis. We were able to show that, under our 
experimental conditions, sodium arsenite effect is limited to Se incorporation and does not 
extend to total protein synthesis. This is consistent with our in vitro studies where arsenite 
directly inhibits SPS. 
 
 
4.4-Keratinocytes exposure to arsenite  
SPS is inhibited in vitro by arsenite and there is a decrease in new selenoprotein 
synthesis. To investigate the effects of arsenite for a short period of time, we cultured HaCaT 
cells for 3 days. Western blots analysis showed a steady level of Gpx and TrxR before and after 
exposure to 2 µM arsenite. When we analyzed the activity of Gpx and TrxR, we still did not see 
any effect. The enzymes activity was constantly normal. This led us to extend the period of 
exposure to arsenite. 
Based on the lack of effect with the short term exposure, we cultured the HaCaT cells in 
DMEM for 6weeks with 0.5 and 1 µM arsenite, 4 passages. Higher concentration (4 µM) killed 
the cells after 2 weeks. In this study, although the cells survived, we were not able to detect any 
change in Gpx and TrxR levels or activities. Also, concentrations up to 16 µM of arsenite did not 
 72
affect the cell proliferation rate for short periods of time (less than 48 hours). The keratinocytes 
are resistant to even long term exposure to arsenite which is in contradiction with our labeling 
experiments and in vitro study. 
From these results, it is possible that arsenite inhibition is overcome by the cells using an 
alternate selenium source present in the medium. Hence, we decided to culture the 
keratinocytes in a defined basal medium.  
 
 
4.5-Keratinocytes culture in defined medium  
In DMEM supplemented with serum, other sources of selenium are available to the cells. 
To control the Se supply, we cultured the HaCaT cells in defined medium which contains only 
one form of Se and at low level. The cells are then treated with 2 and 4 µM arsenite for 3 days. 
Arsenite affected the cell proliferation rate in defined medium but failed to generate any change 
at the protein level as well as enzyme activity level for Gpx and TrxR. 
These initial studies in defined medium have yet to show an effect on TrxR and Gpx 
levels, however these cells were not transitioned into defined medium, so further study is needed 








CHAPTER FIVE: CONCLUSION 
In conclusion, in this study we have demonstrated that, in vitro, arsenite inhibits 
selenophosphate synthetase by competition with the substrate, sodium hydrogen selenide. We 
also observed a decrease in Se incorporation proportional to the increase in arsenite 
concentration; yet, we couldn’t detect any correlation between Se incorporation and levels and 
activity of two selenoproteins essential in defense against oxidative damage (Gpx, TrxR). It has 
been proven that oxidative damage occurs after exposure to arsenicals. Our results might suggest 
the existence of a secondary pathway that would counteract the inhibitory effects of arsenite by 
incorporating into the cell a different form of selenium whenever the primary form of choice is 
depleted. In consequence, our revised hypothesis is that arsenic only affects certain selenium 
compounds. 
Studies to elucidate a possible secondary pathway of selenoprotein biosynthesis are 
ongoing and will allow to better understand the molecular mechanism of arsenic-induced 
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